Karpas Strategies LLC Acquires 97 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on May 8th, 2023

Karpas Strategies LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 134,113 shares of the company’s stock after purchasing an additional 97 shares during the period. Johnson & Johnson makes up approximately 8.3% of Karpas Strategies LLC’s investment portfolio, making the stock its largest holding. Karpas Strategies LLC’s holdings in Johnson & Johnson were worth $23,691,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth about $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson during the fourth quarter worth about $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson during the third quarter worth about $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter worth about $52,000. Finally, Iron Horse Wealth Management LLC grew its holdings in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after acquiring an additional 159 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.3 %

Shares of Johnson & Johnson stock opened at $162.68 on Monday. The firm has a market cap of $422.76 billion, a price-to-earnings ratio of 34.03, a P/E/G ratio of 2.78 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.77. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The stock has a 50-day simple moving average of $158.33 and a 200-day simple moving average of $166.98.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. During the same period last year, the business earned $2.67 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. Raymond James lowered their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. StockNews.com began coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. SVB Leerink decreased their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Finally, Credit Suisse Group raised their price objective on Johnson & Johnson from $168.00 to $170.00 in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $173.00.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is owned by company insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.